Association of Stroke Severity With Efficacy of Early Tirofiban Infusion After Intravenous Thrombolysis

Background This study aims to assess the effects of stroke severity at admission on the efficacy and safety of early tirofiban infusion following intravenous thrombolysis in patients with acute ischemic noncardioembolic stroke using data from the ASSET‐IT (Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis) trial. Methods All 832 patients with acute ischemic noncardioembolic stroke from the ASSET‐IT database were included in this exploratory post hoc analysis. The primary efficacy and safety outcomes were an excellent functional outcome (modified Rankin Scale score of 0–1 at 90 days) and intracranial hemorrhage. Results Among the 832 patients included, the median age was 69 (interquartile range, 59–76) years, 531 (63.8%) were men, 367 (44.1%) had minor stroke (National Institutes of Health Stroke Scale score <6), and 465 (55.9%) had moderate‐to‐severe stroke (National Institutes of Health Stroke Scale score ≥6). There were significant interactions between the primary efficacy and safety outcomes ( P interaction =0.008, P interaction =0.03; respectively). We observed that among patients with NIHSS score ≥6, tirofiban markedly increased odds of achieving an excellent functional outcome (adjusted odds ratio, 2.13 [95% CI, 1.44–3.17]; P <0.001) without significantly increasing the risk of intracranial hemorrhage (adjusted odds ratio, 0.88 [95% CI, 0.37–2.09]; P =0.77). In contrast, no significant benefit was observed in the National Institutes of Health Stroke Scale score <6 group (adjusted odds ratio, 1.02 [95% CI, 0.64–1.63]; P =0.94) but there was a significant increase in the risk of intracranial hemorrhage (adjusted odds ratio, 6.51 [95% CI, 1.42–62.03]; P =0.01). Conclusions Early tirofiban infusion may be more beneficial for patients with moderate‐to‐severe stroke treated with intravenous thrombolysis within 4.5 hours of onset, while simultaneously suggesting an increased potential risk of intracranial hemorrhage in minor stroke. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06134622.

Authors

Institutions

Publication Details

Journal
Journal of the American Heart Association
Published
2026-11-12
DOI
https://doi.org/10.1161/jaha.126.049693
Primary Topic
Acute Ischemic Stroke Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association of Stroke Severity With Efficacy of Early Tirofiban Infusion After Intravenous Thrombolysis

Huihan Xie, Chunrong Tao, Wei Hu, Rui Li et al.
Journal of the American Heart Association
Acute Ischemic Stroke Management
article

Association of Stroke Severity With Efficacy of Early Tirofiban Infusion After Intravenous Thrombolysis

Huihan Xie, Chunrong Tao, Wei Hu, Rui Li, Yuyu Zhou, Yiran Chen, Ruolan Zhu, Tianlong Liu, Qian Qiao
article en

Abstract

Background This study aims to assess the effects of stroke severity at admission on the efficacy and safety of early tirofiban infusion following intravenous thrombolysis in patients with acute ischemic noncardioembolic stroke using data from the ASSET‐IT (Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis) trial. Methods All 832 patients with acute ischemic noncardioembolic stroke from the ASSET‐IT database were included in this exploratory post hoc analysis. The primary efficacy and safety outcomes were an excellent functional outcome (modified Rankin Scale score of 0–1 at 90 days) and intracranial hemorrhage. Results Among the 832 patients included, the median age was 69 (interquartile range, 59–76) years, 531 (63.8%) were men, 367 (44.1%) had minor stroke (National Institutes of Health Stroke Scale score <6), and 465 (55.9%) had moderate‐to‐severe stroke (National Institutes of Health Stroke Scale score ≥6). There were significant interactions between the primary efficacy and safety outcomes ( P interaction =0.008, P interaction =0.03; respectively). We observed that among patients with NIHSS score ≥6, tirofiban markedly increased odds of achieving an excellent functional outcome (adjusted odds ratio, 2.13 [95% CI, 1.44–3.17]; P <0.001) without significantly increasing the risk of intracranial hemorrhage (adjusted odds ratio, 0.88 [95% CI, 0.37–2.09]; P =0.77). In contrast, no significant benefit was observed in the National Institutes of Health Stroke Scale score <6 group (adjusted odds ratio, 1.02 [95% CI, 0.64–1.63]; P =0.94) but there was a significant increase in the risk of intracranial hemorrhage (adjusted odds ratio, 6.51 [95% CI, 1.42–62.03]; P =0.01). Conclusions Early tirofiban infusion may be more beneficial for patients with moderate‐to‐severe stroke treated with intravenous thrombolysis within 4.5 hours of onset, while simultaneously suggesting an increased potential risk of intracranial hemorrhage in minor stroke. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06134622.

Journal of the American Heart Association
University of Science and Technology of China (CN)
Good health and well-being
Acute Ischemic Stroke Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon